Skip to main content

Table 2 CSF Analysis on Weekly 50 mg IT Trastuzumab

From: Intrathecal trastuzumab: immunotherapy improves the prognosis of leptomeningeal metastases in HER-2+ breast cancer patient

Week

1

2

3

4

Protein (g/L)

31

52a

50a

68a

RBC (/cmm3)

519

74

15

<1

WBC (/cmm3)

<1

3

2

<1